Raphi Levy on clinical trial expansion
From Alpha Tau Medical (DRTS) Investor Presentation | Lytham Partners Spring 2026 Investor Conference · · Lytham Partners
“We announced very recently that the FDA expanded this study to be 20 patients in each cohort, 40 patients total. And patients who are receiving either FOLFIRINOX or gemcitabine and nab-paclitaxel, those are the two standards of care for these patients. And so obviously excited to see a bigger study and more patients coming in so that when we ultimately move into a pivotal trial, if these data look good, we can look go after a broader label across really almost all the patients who are newly diagnosed.”
On , Raphi Levy, CFO at Alpha Tau Medical, spoke about clinical trial expansion during Alpha Tau Medical (DRTS) Investor Presentation | Lytham Partners Spring 2026 Investor Conference on Lytham Partners.
About Raphi Levy
Raphi Levy, CFO of Alpha Tau Medical, presented at the Lytham Partners Spring 2026 Investor Conference on May 27, 2026. He stated that the company had $80 million in cash at the end of the previous quarter and described a burn rate approaching $25 million per year, adding that the company is "well financed for execution." Levy highlighted several clinical trials, including a pancreatic cancer study (Impact) and a brain cancer study (Regain), and noted that final results from a first-in-human pancreatic cancer trial were being presented at ASCO 2026. He said that in an earlier interim analysis of metastatic pancreatic cancer patients who had failed FOLFIRINOX, median survival had not been reached at 15 months of follow-up, compared to an expected 10–11 months per literature. Levy also discussed updates to a pancreatic cancer study, stating that the FDA expanded it to 40 patients across two cohorts receiving either FOLFIRINOX or gemcitabine with nab-paclitaxel. In a separate trial combining Alpha DaRT with Keytruda, he reported that two of three patients had a complete response and the third had stable disease, describing the 67% complete response rate as "completely unheard of" while noting the data are early. He contrasted this with Keytruda alone, which he said is expected to produce a 19% response rate and a 5% systemic complete response rate. Levy said the company is in discussions with the FDA about launching a larger U.S. study for approval in certain patients.